CSIMarket
 
Alvotech  (NASDAQ: ALVO)
Other Ticker:  
 
 
Price: $9.0100 $-0.21 -2.278%
Day's High: $9.21 Week Perf: -10.88 %
Day's Low: $ 8.98 30 Day Perf: -13.86 %
Volume (M): 143 52 Wk High: $ 13.79
Volume (M$): $ 1,291 52 Wk Avg: $11.48
Open: $9.20 52 Wk Low: $7.35



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 425
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 66
 Capital Exp. (TTM) (Millions $) 33

Alvotech


   Company Address: 9 Luxembourg 1273
   Company Phone Number: 422 4500   Stock Exchange / Ticker: NASDAQ ALVO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -1.51%    
BIIB   -3.28%    
EXEL   -2.49%    
GILD   -0.94%    
HALO   -2.55%    
MOLN   -2.05%    
• View Complete Report
   



Equity Market Information

Expanding Horizons Alvotechs Successful Private Placement and Its Implications for Biosimilar Development

Published Wed, Jun 11 2025 9:48 PM UTC

The biotechnology landscape is continuously evolving, driven by scientific advancements and the growing demand for affordable therapies. A notable development in this sector is the recent private placement completed by Alvotech (NASDAQ: ALVO, ALVOSDB), a leading biopharmaceutical company known for its focus on biosimilar medicines. This significant financial maneuver, which...

Equity Market Information

for the Alvotech Eyes Strategic Growth Private Placement and Revenue Stability Amidst Competitive Headwinds...

Published Wed, Jun 4 2025 4:06 PM UTC

Alvotech, a dedicated biotechnology company specializing in the development of high-quality biosimilars, has announced its intention to engage in a private placement of approximately 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares. This financial maneuver comes at a pivotal moment for the company, as it marks a strategic step in bolstering its resources a...

Announcement

Alvotech?s Strategic Future Navigating the Waters of Industry Challenges Through Governance and Financial Performance

Published Tue, May 27 2025 9:38 AM UTC

As preparations ramp up for Alvotech s Annual General Meeting on June 25, 2025, at the esteemed premises of Arendt & Medernach in Luxembourg, the company stands poised at a critical juncture in its development. This meeting not only marks an essential ritual of corporate governance but also serves as a platform for stakeholders to engage in candid discussions about the compa...

Announcement

Alvotech Engages Investors at BofA Securities Healthcare Conference 2025 Amid Positive Developments in Biosimilars,

Published Fri, May 9 2025 4:29 PM UTC

Alvotech (NASDAQ: ALVO), a prominent global biotech company dedicated to the development and manufacture of biosimilar medicines, is gearing up for its participation in the upcoming BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada, scheduled for May 13-15, 2025. The event serves as a platform for the company to engage with investors, presenting a unique opport...

Equity Market Information

In a significant development for the global biosimilars market, Alvotech (NASDAQ ALVO), a leading biotech f...

Published Thu, Mar 20 2025 7:58 AM UTC

Alvotech Bolsters Global Biosimilar Leadership through Acquisition of Xbrane s R&D Operations in Sweden In a significant development for the global biosimilars market, Alvotech (NASDAQ: ALVO), a leading biotech firm renowned for its focus on biosimilar medicines, has announced the strategic acquisition of the Research and Development (R&D) operations of Xbrane Biopharma AB, ...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com